GlassScriptPhysician profile
Susan Flanzman
NPI 1609870245
$3,453.39
in general payments reported to CMS, 2019-2025
45 companies · $741 in 2025
The $741 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $192 · 2022: $401 · 2023: $703 · 2024: $542 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $447.24 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $320.08 | 2020-2025 | |
| Amgen INC. | $275.55 | 2019-2025 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $200.67 | 2019-2025 | Entyvio, Trintellix |
| Ucb, INC. | $177.96 | 2020-2025 | Bimzelx, Cimzia |
| Novo Nordisk INC | $177.65 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Biotech, INC. | $172.73 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Glaxosmithkline, LLC. | $164.63 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $141.63 | 2019-2025 | Veozah |
| Pfizer INC. | $141.50 | 2019-2025 | |
| Lilly USA, LLC | $131.92 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Medtronic, INC. | $108.61 | 2022-2023 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $107.63 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $86.10 | 2019-2024 | Lagevrio |
| Shire North American Group INC | $68.42 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Flanzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.